Avantium NV Formerly known as Avantium Holding BV. Avantium NV, formerly Avantium Holding BV, is a company based in the Netherlands engaged in environmental research and development (R&D). The Company develops chemical technologies and production processes to convert bio-based feedstock into sustainable products. The Company's business comprises three segments: Catalysis, Renewable Chemistries, and YXY. Catalysis segment provides catalysis R&D services and systems to chemical, refinery and energy companies, utilizing its Flowrence Technology Platform to devise the appropriate catalyst testing solutions. Renewable Chemistries is the development division with a portfolio of projects focusing on the conversion of biomass to chemical building blocks and plastic materials. The YXY segment comprises the activities of Syviana, the joint venture with BASF SE. The YXY technology is used to convert plant-based sugars into chemical building blocks for plastics, such as polymer polyethylenefuranoate (PEF), and other applications.

Fagron supplies products, services to professionals and institutions in the healthcare sector in Europe, the U.S.A. and Brazil. Co.'s activities are subdivided into four divisions. Through Fagron, Co. offers products and concepts for pharmaceutical compounding. Through Arseus Dental, Co. supplies dental products and concepts to dentists and dental laboratories in Belgium, the Netherlands, France, Germany and Switzerland. Through Arseus Medical, Co. supplies medical and surgical products to specialists, elderly homes, homecare nurses and hospitals in Belgium and the Netherlands. Through Corilus, Co. supplies ICT total solutions for medical specialists in Belgium, the Netherlands and France.

Koninklijke Bam is a construction group based in the Netherlands. Co. is active in the sectors construction, property, civil engineering, public private partnerships, mechanical and electrical contracting, consultancy and engineering, and facilities management. Co. maintais market positions in the Netherlands, Belgium, the United Kingdom, Ireland and Germany. Co. undertakes specialist construction and civil engineering projects in niche markets worldwide. Co.'s consultancy and engineering company provides services to global clients with their international operations.

UCB is a global biopharmaceutical company focused on severe diseases in two therapeutic areas, namely central nervous system disorders and immunology. In the area of central nervous system disorders, Co. is focused on advanced Parkinson's disease, epilepsy, restless legs syndrome and epilepsy. In the area of immunology disorders, Co. is focused on rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, systemic lupus erythematosus, juvenile idiopathic arthritis, post-menopausal osteoporosis, systemic lupus erythematosus and immunological diseases.